Lee, J.H.

patient myeloma response university therapy bortezomib regimen study hospital dexamethasone thalidomide lenalidomide treatment month cancer survival serum combination trial group disease criteria leukemia phase institute recommendation diagnosis table blood palumbo department guideline outcome factor center group guidelines melphalan level mayo clinic progression prednisone stage result clinic hematology grade 100 ml randomized myeloma sk kumar doxorubicin france plasma prince alfred hospital transplantation pegylated liposomal doxorubicin chain relapse cell transplantation chemotherapy transplant evidence agent m-protein marrow myeloma patients cyclophosphamide medicine high-dose dexamethasone oncol response rate fi rst regimen kumar number richardson neuropathy event-free survival reduction increase urine light